Company Profile

PFIZER LTD.

NSE : PFIZERBSE : 500680ISIN CODE : INE182A01018Industry : Pharmaceuticals & DrugsHouse : Pfizer - MNC
BSE4406.50159.6 (+3.76 % )
PREV CLOSE (Rs.) 4246.90
OPEN PRICE (Rs.) 4252.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 3580
TODAY'S LOW / HIGH (Rs.)4252.00 4455.00
52 WK LOW / HIGH (Rs.)2797.5 4929.85
NSE4406.55 156.55 (+3.68 % )
PREV CLOSE(Rs.) 4250.00
OPEN PRICE (Rs.) 4319.95
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 4406.55 (129 )
VOLUME 67262
TODAY'S LOW / HIGH(Rs.) 4302.30 4458.00
52 WK LOW / HIGH (Rs.)2792.25 4925

Company News

Date Heading Details
18-Mar-2020 Pfizer informs about loss of share certificate <P align=justify>Pfizer has informed about loss of share certificate/ issue of duplicate share certificate, pursuant to Regulation 39(3) of SEBI (Listing obligations and disclosure requirement) Regulations 2015..<BR><P align=justify>The above information is a part of company's filings submitted to BSE.<P align=justify><BR><P align=justify><BR><P align=justify><BR>
03-Mar-2020 Pfizer's parent company identifies some antiviral compounds to inhibit coronavirus: Report <p align="justify">Pfizer's parent company in the US has reportedly found some antiviral compounds that have the potential to inhibit coronavirus. The company is engaging with a third party to screen the compounds and it hopes that they would get the results from screening by the end of March. If any of the compounds are successful the company would start testing them by the end of the year.</p><p align="justify">Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.<br></p>
03-Mar-2020 Pfizer soars on the buzz of its parent company identifies some antiviral compounds to inhibit coronavirus <p align="justify">Pfizer is currently trading at Rs. 4416.75, up by 157.90 points or 3.71% from its previous closing of Rs. 4258.85 on the BSE.<p align="justify">The scrip opened at Rs. 4274.95 and has touched a high and low of Rs. 4929.85 and Rs. 4271.15 respectively. So far 36100 shares were traded on the counter.<p align="justify">The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 4,929.85 on 03-Mar-2020 and a 52 week low of Rs. 2797.50 on 23-Aug-2019.<p align="justify">Last one week high and low of the scrip stood at Rs. 4929.85 and Rs. 4054.85 respectively. The current market cap of the company is Rs. 20213.41 crore.<p align="justify">The promoters holding in the company stood at 63.92%, while Institutions and Non-Institutions held 16.72% and 19.36% respectively.<p align="justify">Pfizer's parent company in the US has reportedly found some antiviral compounds that have the potential to inhibit coronavirus. The company is engaging with a third party to screen the compounds and it hopes that they would get the results from screening by the end of March. If any of the compounds are successful the company would start testing them by the end of the year.<p align="justify">Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.</p>
14-Feb-2020 Pfizer informs about issuance of duplicate share certificates <p align="justify">Pfizer has informed that pursuant to Regulation 39(3) and other application regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Registrar and Transfer Agent of the Company, Kfin Technologies has received requests for issue of duplicate Share Certificates from the Shareholders, Salim Majeed Patel and Arati Roy.<p align="justify">The above information is a part of company's filings submitted to BSE.</p>
14-Feb-2020 Pfizer informs about un-audited financial results <p>Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Pfizer has &nbsp;informed that the company has submitted the un-audited financial results for the quarter ended December 31, 2019, which were approved by the Board of Directors of the Company at its Meeting held today, that commenced at 12:00 noon and concluded at 2:00 pm. Also the company has enclosed the Limited Review Report by its Auditors Walker Chandiok &amp; Co LLP, in respect of the results.<p>The above information is a part of company's filings submitted to BSE.<p></p>
14-Feb-2020 Announcement under Regulation 30 (LODR)-Change in Directorate Intimation pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Appointment of Mr. Samir Kazi as an Executive Director.
03-Feb-2020 Board Meeting Intimation for Board Meeting For The Unaudited Financial Results For The Quarter Ended December 31, 2019. PFIZER LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2020 ,inter alia, to consider and approve This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, February 14, 2020, inter alia, to consider and take on record the Unaudited Financial Results of the Company for the quarter ended December 31, 2019. Pursuant to the "Pfizer Limited - Code of Internal Procedures and Conduct to Regulate, Monitor and Report Trading by Insiders', the Trading Window of the Company remains closed from Wednesday, January 1, 2020 till 48 hours after the results are made public on February 14, 2020. We request you to kindly take the same on record.
16-Sep-2019 Pfizer informs about disclosure <p>Pfizer has informed about disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations).&nbsp;<p>The above information is a part of company's filings submitted to BSE.</p>
09-Aug-2019 Pfizer reports 23% rise in Q1 net profit <p align="justify">Pfizer has reported results for first quarter ended June 30, 2019.</p><p align="justify">The company has reported 22.83% rise in its net profit at Rs 112.81 crore for the quarter under review as compared to Rs 91.84 crore for the same quarter in the previous year. Total income of the company increased by 6.89% at Rs 580.23 crore for Q1FY20 as compared Rs 542.84 crore for the corresponding quarter previous year.</p><p align="justify">Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.<br></p>
30-Jul-2019 Pfizer planning to merge off-patent drug business with Mylan <p align="justify">Pfizer is planning to merger its off-patent drug business with generic drugmaker Mylan to create a global leader in low-cost treatment. The new entity, which will be renamed upon the deal's closure, will have a portfolio that includes impotence drug Viagra, cholesterol pills Lipitor, painkiller Lyrica, and the life-saving EpiPen allergy treatment.</p><p align="justify">Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.<br></p>